Primary Brain Tumors / Metastatic Brain Tumors
Summary
Results from a multi-center, prospective study in
patients with a solitary brain metastasis show that
GliaSite Radiation Therapy System (RTS) following surgical removal of the tumor is a
beneficial and well-tolerated treatment option. Local
control of the tumor was 87% with GliaSite RTS and quality
of life was maintained.1-2
Thirteen centers participated in the study including:
- Carolinas Medical Center
- Cleveland Clinic
- Emory University
- H. Lee Moffit Cancer Center
- Henry Ford Hospital
- MD Anderson
- Semmes-Murphey Clinic
- University of Iowa
- University of North Carolina
- University of Pennsylvania
- University of Utah
- Wake Forest University
- Yale University
Patient Demographics
Number of patients treated: 54
Diagnosis: metastatic carcinoma
Average Age: 60 years (range 29-86 years)
Average Karnofsky Performance Score: 90 (range 70-100)
Results
Tumor Control
• Local Control – 87%
• Median local control time was >66 weeks.
• Distant Control – 56%
• Median distant control time was 54 weeks.
Survival is consistent with other treatment modalities.
• Median survival was 40 weeks.
• 11% of deaths classified as Central Nervous
System (CNS) related.
Toxicity
• The safety profile was comparable to this
patient population following craniotomy.
• Reoperation for radiation necrosis occurred in
9 patients at 14-79 weeks.
• Two additional patients were determined to have
mixed tumor and radiation necrosis.
Steroid Administration
• Steroid administration in this study was
comparable to use in this patient population.
Quality of Life
• Median duration of functional independence was
53 weeks.
• Median KPS at one year was 80.
Conclusions
• The encouraging tumor control and quality of
life data indicate that GliaSite may provide benefit to
patients.
• GliaSite RTS should be considered for patients
undergoing surgical resection.
• This local radiation treatment allows for delay
of WBRT.
References:
|
